ReviewAnnals of translational medicine2023
How to improve the sensitivity and specificity of cell-based assays in detecting autoantibodies in neuroimmune diseases.
Review in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A practical alternative to live cell-based assay for AQP4 and MOG antibody detection.EBioMedicine · 2026Article
- Consistent Detection of Aquaporin-4 Antibodies: A Comparative Analysis Between Fixed and Live Cell-Based Assays.Journal of clinical neurology (Seoul, Korea) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies are associated with neuroimmune diseases that affect the central and peripheral nervous systems. There are many methods for detecting autoantibodies, among which cell-based assay (CBA) is a relatively novel and important technology that is widely used. CBAs, as novel indirect immunofluorescence assays with known antigen epitopes, have revolutionized the identification of autoantibodies compared with the traditional immunoassays, such as the radioimmunoprecipitation and enzyme-linked immunosorbent assays, as well as the tissue-based assays (TBAs). However, the results of the same sample might exhibit obvious differences between different laboratories, or among repeated testing in the same laboratory, which influence the sensitivity and specificity in the diagnostic performance for a specific neuroimmune disease. In this paper, we review the establishment of CBA technology, and discuss potential interfering factors in CBA methods on its sensitivity and specificity for the autoantibodies associated with neuroimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.